3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
8
Unknown
2
Withdrawn
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
33
Pancreatic Neoplasms
14
Neuroblastoma
12
Neoplasm Metastasis
10
Stomach Neoplasms
8
Neoplasms
8
Rectal Neoplasms
5
Small Cell Lung Carcinoma
4
Esophageal Squamous Cell Carcinoma
4
Colonic Neoplasms
4
Sarcoma, Ewing
3
Rhabdomyosarcoma
3
Ovarian Neoplasms
3
Breast Neoplasms
3
Adenocarcinoma
3
Wilms Tumor
2
Sarcoma
2
Recurrence
2
Osteosarcoma
2
Gastrointestinal Neoplasms
2
Ganglioneuroblastoma
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Biliary Tract Neoplasms
2
Adenocarcinoma Of Esophagus
2
Uterine Neoplasms
1
Triple Negative Breast Neoplasms
1
Stage I Mixed Cell Type Kidney Wilms Tumor
1
Solid Tumors
1
Interventions
Gemcitabine
7
Oxaliplatin
6
Cisplatin
5
durvalumab
3
130-nm albumin-bound paclitaxel
3
pembrolizumab
2
Leucovorin
2
Drug Therapy
2
zanidatamab
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
sintilimab
1
pertuzumab
1
anlotinib
1
Trastuzumab
1
Taxes
1
Standard of Care
1
Platinum
1
Observation
1
Nivolumab
1
Neoadjuvant Therapy
1
Long-Term Synaptic Depression
1
Irinotecan
1
Folfox protocol
1
Fluorouracil
1
Everolimus
1
Commerce
1
Cholangiopancreatography, Endoscopic Retrograde
1
Biopsy
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Gallbladder Neoplasms
×
Irinotecan
×
Clear all
NCT07265674
2026-05-14
Beacon-BTC
J-Pharma Co., Ltd.
Phase 3
Recruiting
480 enrolled